Peripheral Retinal Vascular Biomarkers on Ultra-Widefield OCT Angiography for Severity Grading in Retinitis Pigmentosa.
prospective_cohort · Level II
Where this comes from
- Record sourced from PubMed, PMID 42633834.
- Also identified by DOI 10.1016/j.ajo.2026.08.027.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
To identify peripheral retinal vascular phenotypes in retinitis pigmentosa (RP) using ultra-widefield OCT angiography (UWF-OCTA), validate a quantitative vascular biomarker, and develop a clinically applicable severity grading system. Development and validation of a severity grading system. We analyzed 544 eyes from 272 patients with primary RP from three tertiary centers. Peripheral vascular phenotypes were defined using UWF-OCTA. Structure-function correlations between the CNZ area and multimodal visual functions-including kinetic perimetry (KP), full-field stimulus threshold (FST), and static perimetry (SP)-were evaluated using linear mixed-effects models (LMMs) to account for inter-eye correlation. A four-stage severity grading system was developed using principal component analysis (PCA) to construct a composite functional score and regression tree analysis with cluster bootstrapping (1,000 resamples) to determine optimal CNZ cut-points; the system was then validated in internal and external datasets. Age-related severity distribution was evaluated through a Kaplan-Meier age-at-observation simulation. Two distinct peripheral vascular phenotypes were identified: Type 1 (Terminal Remodeling; 306 eyes, 56.2%) and Type 2 (Simple Atrophy; 238 eyes, 43.8%). Type 1 eyes showed greater disease severity than Type 2 eyes at comparable ages. The CNZ area demonstrated strong structure-function correlations, explaining substantial variance in KP (Marginal R<sup>2</sup> up to 0.77) and FST (Marginal R<sup>2</sup> up to 0.64). A CNZ-based 4-stage severity grading (Stage I, ≥ 260 mm²; Stage II, 200-260 mm²; Stage III, 150-200 mm²; Stage IV, < 150 mm²) effectively stratified disease severity, demonstrating high explanatory power for visual function (KP η² up to 0.75; FST η² up to 0.66) and maintaining discriminatory performance for best-corrected visual acuity (BCVA) in both internal (η² = 0.17) and external (η² = 0.28) validation cohorts. Peripheral retinal vascular alterations captured by UWF-OCTA define distinct RP phenotypes and identify the CNZ as a robust quantitative biomarker of disease severity. The CNZ-based severity grading system provides an objective framework for clinical severity assessment, disease monitoring, and patient stratification in future interventional trials.